 The Star-Ledger - NJ.com | Stock Investors Sell Off Shares of Bristol-Myers Squibb, Down 3.6% Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. There is potential upside of 4.3% for shares of Bristol-Myers ... Bristol-Myers Squibb Higher Ahead of Earnings CITIGROUP RAISED ITS PT FOR BRISTOL-MYERS SQUIBB TO $40 (BMY) |
